Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.77 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.77 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.50 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.50 |
| ▸ | BRS3 | P32247 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330143 | 0.86 | TEAD1 (0.74) | MTNR1AMTNR1BTEAD1CACNA1GCACNA1H | |
| SCHEMBL30576489 | 0.86 | TEAD1 (0.74) | MTNR1AMTNR1BTEAD1CACNA1GCACNA1H | |
| SCHEMBL651178 | 0.86 | MTNR1A (0.60) | MTNR1AMTNR1BTEAD1CACNA1GCACNA1H | |
| SCHEMBL30478647 | 0.84 | MTNR1A (0.70) | MTNR1AMTNR1BTEAD1CACNA1GCACNA1H | |
| SCHEMBL1982456 | 0.84 | MTNR1A (0.70) | MTNR1AMTNR1BTEAD1CACNA1GCACNA1H | |
| SCHEMBL431819 | 0.82 | TEAD1 (0.61) | MTNR1AMTNR1BTEAD1SIRT1MEN1 | |
| SCHEMBL3287060 | 0.81 | MTNR1A (0.54) | MTNR1AMTNR1BTEAD1BRD4MEN1 | |
| SCHEMBL25330360 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BTEAD1MEN1ALDH1A1 | |
| SCHEMBL431599 | 0.79 | MTNR1A (0.60) | MTNR1AMTNR1BCACNA1GCACNA1HCACNA1I | |
| SCHEMBL7698967 | 0.78 | MTNR1A (0.50) | MTNR1AMTNR1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | MTNR1A 1460/4885MTNR1B 1468/4885TEAD1 3/4885 |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | MTNR1A 59/4885MTNR1B 98/4885TEAD1 1626/4885 |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | MTNR1A 4148/4885MTNR1B 4147/4885TEAD1 349/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | MTNR1A 48/4885MTNR1B 92/4885TEAD1 1819/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | MTNR1A 59/4885MTNR1B 98/4885TEAD1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.